OSE: target achieved for Tedopi, share price rises

(CercleFinance.com) - OSE Immunotherapeutics climbed more than 15% on the Paris Bourse on Wednesday, after announcing that Tedopi had increased the survival rate of pancreatic cancer patients, meeting its primary objective in a Phase 2 trial.


This non-comparative study, conducted by the Gercor group of oncology clinicians, was designed to evaluate this therapeutic vaccine in combination with chemotherapy in advanced or metastatic pancreatic adenocarcinoma (ADCP).

A total of 107 patients were included in the trial.

In its press release, OSE simply states that the study met its primary objective, showing positive results according to the predefined statistical hypotheses, with minimal toxicity, without providing any further details.

The 'biotech', which stresses that patient follow-up is ongoing, plans to present more detailed results at a forthcoming medical congress.

Note that the main Tedopi program is focused on non-small cell lung cancer (NSCLC), and is due to be completed in 2027," Edison analysts wrote in a note today.

Copyright (c) 2025 CercleFinance.com. All rights reserved.